These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31288852)

  • 1. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion.
    Cheaney B; Bowden S; Krause K; Sloan EA; Perry A; Solomon DA; Han SJ; Wood MD
    Acta Neuropathol Commun; 2019 Jul; 7(1):110. PubMed ID: 31288852
    [No Abstract]   [Full Text] [Related]  

  • 2. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
    Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
    Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic landscape of ganglioglioma.
    Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
    Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
    Marker DF; Pearce TM
    Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative and Qualitative Parameters of DCE-MRI Predict CDKN2A/B Homozygous Deletion in Gliomas.
    Yang H; Zhu Z; Long C; Niu F; Zhou J; Chen S; Ye M; Peng S; Zhang X; Chen Y; Wei L; Wang H; Liu D; Yao M; Zhang X; Zhang B
    Acad Radiol; 2024 Aug; 31(8):3355-3365. PubMed ID: 38443208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
    Saxena A; Robertson JT; Ali IU
    Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
    Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
    Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p16
    Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
    J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    Vizcaino MA; Giannini C; Lalich D; Nael A; Jenkins RB; Tran Q; Orr BA; Abdullaev Z; Aldape K; Vaubel RA
    J Neuropathol Exp Neurol; 2024 May; 83(6):416-424. PubMed ID: 38699943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients.
    Bassi CL; Martelli L; Cipolotti R; Scrideli CA; Defávery R; Tone LG
    Braz J Med Biol Res; 2004 Nov; 37(11):1683-7. PubMed ID: 15517085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
    Kim M; Yim SH; Cho NS; Kang SH; Ko DH; Oh B; Kim TY; Min HJ; She CJ; Kang HJ; Shin HY; Ahn HS; Yoon SS; Kim BK; Shin HR; Han KS; Cho HI; Lee DS
    Cancer Genet Cytogenet; 2009 Nov; 195(1):59-65. PubMed ID: 19837270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
    Sonoda Y; Yoshimoto T; Sekiya T
    Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
    Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
    Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.
    Dyke J; Calapre L; Beasley A; Gray E; Allcock R; Bentel J
    Pathol Res Pract; 2022 Jan; 229():153724. PubMed ID: 34942511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion.
    Chonabayashi K; Tamori S; Taniwaki M; Fujita H; Shimazu Y; Matsui Y; Hishizawa M; Usami K; Takaori-Kondo A
    Ann Hematol; 2014 May; 93(5):893-4. PubMed ID: 23989669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.